Back to results
US 2007/0190055 A1Published application
CCR3 inhibition for ocular angiogenesis and macular degeneration
AssigneeUniversity of Kentucky Research Foundation
InventorJayakrishna Ambati
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Claims21
A method of inhibiting ocular angiogenesis comprising exposing a choroidal cell to a CCR3-inhibitory effective amount of a compound which inhibits the activity of CCR3.
A composition for the inhibition of ocular angiogenesis comprising a compound which inhibits the activity of CCR3.
Dependencies are inferred from the claim text.